

Editorial

Special Issue: “Neurodegenerative Diseases: Recent Advances and Future Perspectives”

Inés López-Cuenca ^{1,2}  and Rosa De Hoz ^{1,2,*} ¹ Ramon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain; inelopez@ucm.es² Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain

* Correspondence: rdehoz@med.ucm.es

Neurodegenerative diseases include a heterogeneous group of conditions that pose a growing challenge to public health and the scientific community [1]. As the worldwide population ages, the impact of these diseases is increasing [2], underscoring the urgent need to improve our understanding of them. In all of the publications in this Special Issue, we have taken an in-depth look at the latest advances in the understanding, diagnosis and treatment of these complex diseases that affect millions of people worldwide [3].

In this Special Issue, we have compiled innovative research covering various aspects related to neurodegenerative diseases: advances in monitoring the progression of Huntington’s disease and multiple sclerosis [4], therapies aimed at improving executive function in mild cognitive impairment (MCI), as well as ocular imaging techniques for diagnosis and monitoring, and risk factor analysis [5]. Literature reviews have also been included to update the materials used in peripheral nervous system therapies, neuroprotective compounds, as well as the most advanced techniques in animal model research [6].

From these studies, it is essential to identify biomarkers and early diagnostic methods [7]. It is crucial to intervene before symptoms arise or in the early stages of these diseases, when therapeutic interventions can be most effective [8]. Research in this area is advancing rapidly, and the studies presented here offer promising prospects for the development of more accurate and non-invasive diagnostic tools.

In addition, tools that allow the monitoring of neurodegenerative pathology, such as the Total Functional Capacity score in Huntington’s disease, are indispensable. Another area of interest in the Special Issue is the exploration of risk factors associated with the development of these pathologies, such as depression, medication use and genetics.

We should not ignore the research on various therapeutic pathways compiled in this Special Issue, such as the use of piezoelectric materials or the neuroprotective potential of fisetin [9].

As the heterogeneity of the publications included here demonstrates, these diseases can be studied from a variety of angles, underscoring the importance of fostering interdisciplinary collaboration and knowledge sharing within the scientific community.

In summary, this Special Issue of *Biomedicines* provides a comprehensive and up-to-date overview of the latest advancements in the field of neurodegenerative diseases. Although we recognize that much work remains to be done, we trust that the knowledge and ideas presented here will serve as a platform for future research and interdisciplinary collaborations, with the aim of achieving a better understanding and treatment of these diseases.

We express our sincere gratitude to all the authors, reviewers, and contributors who have made this Special Issue possible. Their dedication and contributions are essential to advancing scientific knowledge and improving the quality of life of those affected by neurodegenerative diseases.

We hope that readers will find these papers inspiring and that they will spur others on to carry out further research and discovery in this crucial field.



Citation: López-Cuenca, I.; De Hoz, R. Special Issue: “Neurodegenerative Diseases: Recent Advances and Future Perspectives”. *Biomedicines* **2024**, *12*, 1080. <https://doi.org/10.3390/biomedicines12051080>

Received: 24 April 2024

Revised: 29 April 2024

Accepted: 7 May 2024

Published: 13 May 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Author Contributions: I.L.-C. and R.D.H. served as Guest Editors of the Special Issue “Neurodegenerative Diseases: Recent Advances and Future Perspectives” and wrote the editorial. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Erkinen, M.G.; Kim, M.O.; Geschwind, M.D. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harb. Perspect. Biol.* **2018**, *10*. [[CrossRef](#)]
2. Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S.G.; Croteau, D.L.; Bohr, V.A. Ageing as a Risk Factor for Neurodegenerative Disease. *Nat. Rev. Neurol.* **2019**, *15*, 565–581. [[CrossRef](#)] [[PubMed](#)]
3. Bongioanni, P.; Del Carratore, R.; Corbianco, S.; Diana, A.; Cavallini, G.; Masciandaro, S.M.; Dini, M.; Buizza, R. Climate Change and Neurodegenerative Diseases. *Environ. Res.* **2021**, *201*. [[CrossRef](#)]
4. Gil-Casas, A.; Piñero, D.P.; Molina-Martín, A. Dynamic Pupillary Response in Multiple Sclerosis Patients with and without Optic Neuritis. *Biomedicines* **2023**, *11*, 3332. [[CrossRef](#)]
5. Wang, W.; Zhang, L.; Cao, W.; Xia, K.; Huo, J.; Huang, T.; Fan, D. Systematic Screening of Associations between Medication Use and Risk of Neurodegenerative Diseases Using a Mendelian Randomization Approach. *Biomedicines* **2023**, *11*, 1930. [[CrossRef](#)] [[PubMed](#)]
6. Sánchez-Puebla, L.; López-Cuenca, I.; Salobrar-García, E.; Ramírez, A.I.; Fernández-Albarral, J.A.; Matamoros, J.A.; Elvira-Hurtado, L.; Salazar, J.J.; Ramírez, J.M.; de Hoz, R. OCT Imaging in Murine Models of Alzheimer’s Disease in a Systematic Review: Findings, Methodology and Future Perspectives. *Biomedicines* **2024**, *12*, 528. [[CrossRef](#)] [[PubMed](#)]
7. Hansson, O. Biomarkers for Neurodegenerative Diseases. *Nat. Med.* **2021**, *27*, 954–963. [[CrossRef](#)] [[PubMed](#)]
8. Ogbodo, J.O.; Agbo, C.P.; Njoku, U.O.; Ogugofor, M.O.; Egba, S.I.; Ihim, S.A.; Echezona, A.C.; Brendan, K.C.; Upaganlawar, A.B.; Upasani, C.D. Alzheimer’s Disease: Pathogenesis and Therapeutic Interventions. *Curr. Aging Sci.* **2022**, *15*, 2–25. [[CrossRef](#)] [[PubMed](#)]
9. Tang, X.; Deng, P.; Jiang, Y.; Zhang, L.; He, Y.; Yang, H. An Overview of Recent Advances in the Neuroprotective Potentials of Fisetin against Diverse Insults in Neurological Diseases and the Underlying Signaling Pathways. *Biomedicines* **2023**, *11*, 2878. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.